This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 5148657 results found since Jan 2013.

New multiple sclerosis severity model predicts future accumulation of disability (P1.373)
Conclusions:This represents a much needed tool for genotype-phenotype correlations, for identifying biological processes that underlie MS progression, and for aiding clinicians and patients in therapeutic decisions.Study Supported by: Intramural research program of NIH/NINDSDisclosure: Dr. Bielekova received patent royalty payments from National Institutes of Health. Dr. Barbour has nothing to disclose. Dr. Tapia Maltos has nothing to disclose. Dr. Weideman has nothing to disclose. Dr. Kosa has nothing to disclose. Dr. Komori has nothing to disclose. Dr. Johnson has nothing to disclose. Dr. Greenwood has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Bielekova, B., Barbour, C., Maltos, M. T., Weideman, A., Kosa, P., Komori, M., Johnson, K., Greenwood, M. Tags: Tools and Measures for Clinical Evaluation in Multiple Sclerosis Source Type: research

Rebound of Multiple Sclerosis Disease Activity Following Fingolimod Cessation (P2.402)
Conclusions:These cases along with similar reports in the literature highlight the need to establish a scheme for switching from fingolimod to other therapies. Further investigations that incorporate patients who have discontinued fingolimod for reasons other than highly active MS, such as adverse effects of fingolimod or progression to secondary progressive MS, can help to identify predictors of MS rebound after fingolimod discontinuation.Disclosure: Dr. Garjani has nothing to disclose. Dr. Nikfekr has nothing to disclose. Dr. George has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Garjani, A., Nikfekr, E., George, J. Tags: Discontinuation and Switching Disease Modifying Therapies in Multiple Sclerosis Source Type: research

The Economic Burden of Moderate-to-Severe Multiple Sclerosis Relapse in the United States: Findings from a Systematic Literature Review (P3.402)
Conclusions:Current literature underappreciates the economic burden of moderate-to-severe MS relapse in terms of frequency, duration, and impacts. Exploration into implications for relapse awareness, characterization, and management, including a thorough evaluation of available treatment options, is warranted.Study Supported by: Mallinckrodt PharmaceuticalsDisclosure: Ms. Nazareth has received personal compensation for activities with Mallinckrodt Pharmaceuticals. Dr. Purser has nothing to disclose. Dr. Bhaila has nothing to disclose. Dr. Philbin has received personal compensation for activities with Mallinckrodt Pharmaceu...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Nazareth, T., Purser, M., Bhaila, R., Philbin, M., Mladsi, D. Tags: Economic Implications of Multiple Sclerosis Source Type: research

Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue
Conclusions Our meta-analysis showed that modafinil was an effective pharmacologic therapy for MS fatigue. Additional research is required to determine optimal dosing and treatment schedules.
Source: Multiple Sclerosis and Related Disorders - October 18, 2017 Category: Neurology Source Type: research

Heart Rate Variability Analysis in Patients with Multiple Sclerosis
Conclusion These findings reveals that our study population with multiple sclerosis had decreased heart rate variability compared to healthy controls. This was reflected by dysfunction of both parasympathetic and sympathetic parameters of hearth rate variability analysis. However, there is no significant relationship between hearth rate variability analysis and the findings on cranial, cervical, thoracic spinal magnetic resonance imaging findings, number of attack, Expanded Disability Status Scale score or Multiple Sclerosis Functional Composite scores in patients with multiple sclerosis.
Source: Multiple Sclerosis and Related Disorders - June 19, 2018 Category: Neurology Source Type: research

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
This study provides Class II evidence that masitinib 4.5 mg/kg/d decreased progression of disability, measured by the EDSS, in adults with PPMS or patients with nSPMS (with no exacerbations in the last 2 years).
Source: Neurology Neuroimmunology and Neuroinflammation - February 21, 2022 Category: Neurology Authors: Vermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., on behalf of the AB07002 Study Group, on behalf of the AB07002 Study Group Tags: Clinical trials Randomized controlled (CONSORT agreement), Class II, Multiple sclerosis Article Source Type: research

Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis
This study aimed to analyze longitudinal dynamics of the retinal vasculature following an acute inflammatory relapse including acute optic neuritis (ON) and to search for associations with alterations of the retinal architecture and visual function. Methods This prospective longitudinal cohort study included patients with relapsing-remitting MS or clinically isolated syndrome having an acute ON (n = 20) or a non-ON relapse (n = 33). Patients underwent examinations at baseline and after 7, 14, 28, 90, and 180 days with OCT, OCT-A, and assessment of the high- (HCVA) and low-contrast visual acuity (LCVA). Results Retinal ve...
Source: Neurology Neuroimmunology and Neuroinflammation - March 17, 2022 Category: Neurology Authors: Aly, L., Noll, C., Wicklein, R., Wolf, E., Romahn, E. F., Wauschkuhn, J., Hosari, S., Mardin, C., Berthele, A., Hemmer, B., Korn, T., Knier, B. Tags: Optic nerve, Multiple sclerosis, Optic neuritis; see Neuro-ophthalmology/Optic Nerve Research Article Source Type: research

Clinical Practice Guidelines for the Detection and Treatment of Depression in Multiple Sclerosis: A Systematic Review
Purpose of Review The association of multiple sclerosis (MS) with depression has been well documented; however, it frequently remains undiagnosed, untreated, or undertreated, with consequences to the person, family, and economy. The aim of this study was to determine the quality, scope, and consistency of available guidelines and consensus statements to guide clinicians managing people with comorbid MS and depression. Recent Findings Based on our systematic search of the literature, 6 guidelines and consensus statements met the inclusion criteria. Of these, 4 presented recommendations on depression screening in MS and 5 o...
Source: Neurology Clinical Practice - April 25, 2023 Category: Neurology Authors: McIntosh, G. E., Liu, E. S., Allan, M., Grech, L. B. Tags: Depression, Multiple sclerosis Review Source Type: research

Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov
Conclusions Phase III and IV clinical trials on MS drugs are prone to under-reporting and publication bias. Efforts must be made to promote a complete and accurate dissemination of data in MS clinical research.
Source: Journal of Neurology, Neurosurgery and Psychiatry - July 13, 2023 Category: Neurosurgery Authors: Rivero-de-Aguilar, A., Perez-Rios, M., Ruano-Ravina, A., Candal-Pedreira, C., Puente-Hernandez, M., Ross, J. S., Varela-Lema, L. Tags: Multiple sclerosis Source Type: research

Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis
The influence of pregnancy on the course of multiple sclerosis (MS) has long been controversial. While historical evidence suggests a substantial decline in relapse rates during pregnancy followed by a rebound in the postpartum period, more recent work yielded equivocal results. We performed a systematic review and meta-analysis on data from cohort studies to determine whether women with MS experience increased relapse rates after delivery. A systematic literature search was conducted in the databases MEDLINE and Epistemonikos on the topic ‘motherhood choice in MS’ in March 2022. We included cohort studies asse...
Source: Journal of Neurology, Neurosurgery and Psychiatry - August 14, 2023 Category: Neurosurgery Authors: Schubert, C., Steinberg, L., Peper, J., Ramien, C., Hellwig, K., Köpke, S., Solari, A., Giordano, A., Gold, S. M., Friede, T., Heesen, C., Rahn, A. C. Tags: JNNP Patients' choice Multiple sclerosis Source Type: research

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study
Conclusion PDA-001 infusions were safe and well tolerated in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis patients. No paradoxical worsening of lesion counts was noted with either dose.
Source: Multiple Sclerosis and Related Disorders - November 3, 2014 Category: Neurology Source Type: research

P020 Comparative investigation of different sequences of Magnetic Resonance Imaging such as FLAIR, T2WI and PDWI in detection of Multiple Sclerosis patients referred to Magnetic Resonance Imaging Department of Imam Khomeini Hospital, Urmia, Iran
Conclusion Based on our study, PDWI Magnetic Resonance Imaging sequences is superior than FLAIR or T2WI sequences in detection of Multiple Sclerosis specific plaque in cerebellum.
Source: Multiple Sclerosis and Related Disorders - December 7, 2014 Category: Neurology Source Type: research

The Neuroscience Report—Vol. 16 (August 17, 2015): Multiple Sclerosis
The latest in neuroscience—sorted and summarized for you Welcome to the Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. Volume 16 (August 17, 2015): Multiple Sclerosis Journal Articles Electroconvulsive Therapy in Multiple Sclerosis Sexual Dysfunction and Depression in Individuals with Multiple Sclerosis: Is There a link? Receptor Tyrosine Kinase and Tyrosine Kinase Inhibitor...
Source: Innovations in Clinical Neuroscience - August 17, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Drug Development General Multiple Sclerosis Neurology The Neuroscience Report drug pipeline Source Type: research

Ketamine Therapy for Treatment-resistant Depression in a Patient with Multiple Sclerosis: A Case Report
Conclusion—Ketamine may be an alternative treatment for resistant depression and may have a special use in patients with multiple sclerosis. Introduction Depression is a frequent finding in patients with multiple sclerosis (MS), with the lifetime prevalence rates for major depressive disorder (MDD) ranging from 36 to 54 percent, more than twice of that in the general population.[1] Even with advances in pharmacological options for treating depression, an estimated 33 to 66 percent of patients with MDD in the general population do not respond to the first antidepressant, and a reported 15 to 33 percent of patients do not ...
Source: Innovations in Clinical Neuroscience - February 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Case Report Current Issue Depression Multiple Sclerosis Neurology Psychiatry Psychopharmacology Electroconvulsive therapy Ketamine major depressive disorder treatment-resistant depression Source Type: research

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms
Conclusion A better definition of what constitutes a relapse in MS is urgently needed. From a treatment perspective, the management of relapses, particularly in the emergency department (ED), is highly variable. In general, it is possible that patients are treated with steroids based on symptomatology and an ED physician’s evaluation. It is often difficult in the ED to ascertain baseline status or a deviation from it, and an MRI may or may not be performed in the ED owing to cost and availability. However, if objective MRI data are not the singular surrogate biomarker to validate BBB breach, false-positive cases are prob...
Source: Innovations in Clinical Neuroscience - April 1, 2017 Category: Neuroscience Authors: ICN Online Editor Tags: Commentary Current Issue Devices Evaluations Multiple Sclerosis Neurology Technology acute relapse big data blood brain barrier imaging magnetic resonance imaging MRI MS Source Type: research